prime medicine(PRME) - 2024 Q4 - Annual Results

Exhibit 99.1 Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates -- On track to report initial data from Phase 1/2 clinical trial of PM359 for p47 CGD in 2025-- phox -- IND-enabling studies ongoing for PM577 for Wilson's Disease; expect to file IND and/or CTA in 1H 2026 – -- Additional high-value programs advancing through preclinical development-- Cambridge, Mass., February 28, 2025 – Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a ne ...